Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia

Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia

Author Petrilli, Antonio Sergio Google Scholar
Carlesse, Fabianne Altruda Google Scholar
Pires Pereira, Carlos Alberto Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Background. Fever in neutropenic (FN) patients requires immediate broad-spectrum antibiotics, however, such patients do not represent a homogeneous population and the majority of them are at low risk of developing complication. Gatifloxacin (GA) is an alternative, though it has not been thoroughly studied in Pediatrics yet. the aim of this study was to evaluate oral CA in oncology pediatric patients with FN and low risk of infectious complications. Methods. We conducted a prospective study in patients submitted to chemotherapy and FN, from the ages of 3 to 21 years old, with solid tumors, acute lymphoid leukemia, and lymphomas without comorbidities and treated as Outpatient with oral GA. Safety and adverse effects were monitored. Results. We evaluated 108 patients with 201 episodes of FN. the average age was 10.8 years, 64.8% of the patients were male. Osteosarcoma accounted for 22% of the episodes, rhabdomyosarcoma for 13%, acute lymphoid leukemia, lymphomas and Ewing sarcoma, for 11% each. Among the 174 episodes exclusively treated as outpatients, the average duration of neutropenia was 4.8 days, the average duration of fever was 2.4 days; the average duration of the treatment was 8.1 days. the treatment was successful in 75.9%, analyzing only the first episodes. No patient died during the study. Adverse events included diarrhea, vomiting, increased liver enzymes, arthralgia, and ECG changes. Conclusion. Oral CA is effective and safe in the management of oncology pediatric patients with FN at low risk of infectious complications in the Outpatient setting.
Keywords febrile neutropenia
low risk of infection
Language English
Date 2007-10-15
Published in Pediatric Blood & Cancer. Hoboken: Wiley-liss, v. 49, n. 5, p. 682-686, 2007.
ISSN 1545-5009 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 682-686
Origin http://dx.doi.org/10.1002/pbc.21124
Access rights Closed access
Type Article
Web of Science ID WOS:000249085300015
URI http://repositorio.unifesp.br/handle/11600/30103

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account